MannKind Corp. (MNKD)

[Phaeton]

One of the other uses for Technosphere use is Inhaled oxytocin. Research funded by the Gate's Foundation and other world Health groups including USAID.

Going to Round Six on July 28th, 2016 for Grant funding.

One of the other uses for Technosphere use is Inhaled oxytocin. (No mention by MannKind of their involvement but you will see a Technospere inhaler and mention by the speaker Robin Offord of Mintaka Foundation of a Industry partner.)

Watch this video. In conjunction with the bill and Melinda Gates foundation in a teaching institution in Australia
inhaled Oxytocin video link
Video showing Technosphere (mention of inhaler as being developed by an industry partner--- Must be because of confidentiality agreement no mention of MannKind)



Saving Lives at Birth web link About Round Six competition


Gold Standard Postpartum Hemorrhage Prevention to Women in Greatest Need

Organization: Monash University
Organization Location: Melbourne, Victoria, Australia

Over 300,000 women die each year due to pregnancy-related causes with hemorrhage being the leading cause. Oxytocin is the gold standard therapy to prevent postpartum hemorrhage and is recommended by the WHO to be used at every birth. Oxytocin is currently available as an injection that requires refrigeration to maintain quality and skilled healthcare workers to safely administer the product. These factors significantly limit the availability and impact of this medicine, particularly in resource poor settings. This project seeks to substantially expand access to oxytocin through the development of an affordable, simple to administer inhaled oxytocin delivery system. Using innovative technology, inhaled oxytocin is formulated as a fine powder that can withstand the climatic conditions common in tropical regions without the need for refrigeration. The product therefore removes the requirement for cold chain supply and storage, potentially allows task-shifting to lower tier healthcare and community workers and has the potential to save 146,000 lives over 8 years (www.ic2030.org). This proposal recognizes that the successful implementation of innovations in global health relies not simply on technical effectiveness but also adaption to meet the needs of the local environment to which the innovation is applied. The planned work will ensure that the product design, presentation and implementation will facilitate maximal access and uptake by end users of greatest need.


The Gates foundation competition in Washington, DC July 26 -28, 2016 with USAID and other global health partners:

In its sixth round, 50 promising finalists from nearly 650 applications will come together to compete in the final stage of the 2016 Saving Lives at Birth Grand Challenge. The finalists will gather at the DevelopmentXChange in Washington DC, from July 26-28, 2016. There, they will learn from each other, interact with potential collaborators, and meet technical advisors in a number of discussion groups and one-on-one meetings designed to facilitate further innovation and impact.

Gold Standard Postpartum Hemorrhage Prevention to Women in Greatest Need
Organization: Monash University
Organization Location: Melbourne, Victoria, Australia
Over 300,000 women die each year due to pregnancy-related causes with hemorrhage being the leading cause. Oxytocin is the gold standard therapy to prevent postpartum hemorrhage and is recommended by the WHO to be used at every birth. Oxytocin is currently available as an injection that requires refrigeration to maintain quality and skilled healthcare workers to safely administer the product. These factors significantly limit the availability and impact of this medicine, particularly in resource poor settings. This project seeks to substantially expand access to oxytocin through the development of an affordable, simple to administer inhaled oxytocin delivery system. Using innovative technology, inhaled oxytocin is formulated as a fine powder that can withstand the climatic conditions common in tropical regions without the need for refrigeration. The product therefore removes the requirement for cold chain supply and storage, potentially allows task-shifting to lower tier healthcare and community workers and has the potential to save 146,000 lives over 8 years (.ic2030). This proposal recognizes that the successful implementation of innovations in global health relies not simply on technical effectiveness but also adaption to meet the needs of the local environment to which the innovation is applied. The planned work will ensure that the product design, presentation and implementation will facilitate maximal access and uptake by end users of greatest need.

Round six will be in Washington, DC on July 26, 2016 and it seems to be open to the public.

The Gates foundation competition in conjunction with USAID and several other World Health groups in Washington, DC July 26 -28

Watch the video link -- He is using a Technosphere Inhaler. Round 6 in Washington, DC July 26-28

Robin Offord Mintaka Foundation

Round Six of this Saving Lives at Birth event.